• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Director Nissenson Allen

    5/20/25 4:07:35 PM ET
    $ELTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ELTX alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Nissenson Allen

    (Last) (First) (Middle)
    C/O ELICIO THERAPEUTICS, INC.
    451 D STREET, 5TH FLOOR, SUITE 501

    (Street)
    BOSTON MA 02210

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Elicio Therapeutics, Inc. [ ELTX ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    05/19/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (Right to Buy) $5.84 05/19/2025 A 7,900(1) (1) 05/19/2035 Common Stock 7,900 $0 7,900 D
    Explanation of Responses:
    1. The stock option shall vest and become exercisable in full on the earlier of (A) May 19, 2026, the one-year anniversary of the date of grant and (B) the next annual meeting of the Company's stockholders after the grant date, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date.
    Remarks:
    /s/ Allen Nissenson 05/20/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $ELTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ELTX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ELTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Elicio Therapeutics to Host Virtual KOL Event on June 25, 2025 to Discuss AMP-Powered ELI-002 for the Treatment of KRAS mutation-driven Pancreatic Cancer

      BOSTON, June 17, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (NASDAQ:ELTX, "Elicio" or the "Company")), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that it will host a virtual key opinion leader ("KOL") event on Wednesday, June 25, 2025 at 2:00 PM ET to discuss the significant unmet need and current treatment landscape for mutant-KRAS ("mKRAS") driven pancreatic ductal adenocarcinoma ("PDAC"), one of the most lethal and underserved solid tumors. To register, click here. The event will feature insights from leading experts: Darrell Irvine, Ph.D. - Department of Immunology & Microbiology, The Scri

      6/17/25 8:00:00 AM ET
      $ELTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Elicio Therapeutics Secures $10 Million in Financing

      Funding expected to support operations into Q1 2026. Anticipated AMPLIFY-7P Phase 2 interim analysis expected in Q3 2025. BOSTON, June 04, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (NASDAQ:ELTX, "Elicio" or the "Company")), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that it has entered a $10 million senior secured promissory note (the "Note") with existing investor, GKCC, LLC ("Note Holder" or "GKCC") (the "Note Financing"). The proceeds from the Note Financing, together with Elicio's current cash and cash equivalents, are expected to support Elicio's operations into the first quarter of 2026

      6/4/25 8:00:00 AM ET
      $ELTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Elicio Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Updates

      Interim analysis focused on disease-free survival ("DFS") in randomized Phase 2 AMPLIFY-7P clinical trial expected in Q3 2025 Company has alignment with U.S. Food and Drug Administration ("FDA") on key design elements of planned Phase 3 study of ELI-002 Current cash position expected to support operations beyond anticipated AMPLIFY-7P Phase 2 interim analysis BOSTON, May 13, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (NASDAQ:ELTX, "Elicio" or the "Company")), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today reported financial results for the first quarter ended March 31, 2025, and provided recent corpo

      5/13/25 4:05:00 PM ET
      $ELTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ELTX
    SEC Filings

    See more
    • Elicio Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Elicio Therapeutics, Inc. (0001601485) (Filer)

      6/4/25 8:03:41 AM ET
      $ELTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Elicio Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Elicio Therapeutics, Inc. (0001601485) (Filer)

      5/20/25 8:06:34 AM ET
      $ELTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Elicio Therapeutics Inc.

      10-Q - Elicio Therapeutics, Inc. (0001601485) (Filer)

      5/13/25 4:31:41 PM ET
      $ELTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ELTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Chudnovsky Yekaterina

      4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)

      6/4/25 5:08:28 PM ET
      $ELTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Ashe Carol Gail

      4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)

      5/20/25 4:08:00 PM ET
      $ELTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Nissenson Allen

      4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)

      5/20/25 4:07:35 PM ET
      $ELTX
      Biotechnology: Pharmaceutical Preparations
      Health Care